Resistance to antibiotics has become a major public health problem; at least 25,000 people die in Europe each year as a result of antibiotic-resistant infections. The PACOBURNS project is set up to explore the possibility of using bacteriophages to combat bacterial infections that are resistant to antibiotics, especially skin infections. This project aims to explore the role and potential of bacteriophages as a means of combating bacterial infections, especially against germs that are multi-resistant to antibiotics. It also involves promoting the use of phages as a credible alternative to antibiotics.
Using relevant animal models, PACOBURNS will make it possible to evaluate the therapeutic efficacy, safety and pharmacodynamics of two cocktails of bacteriophages. The first one is designed for infections caused by escherichia coli type bacteria, and the second for infections caused by pseudomonas aeruginosa species, and more specifically for treating open burn wounds infected by these resistant germs. Trials on humans are scheduled to begin early-mid 2013.
This challenge is of concern to the armed forces’ health services, which are encountering increasing resistance to antibiotics in both military personnel and civilians, especially when it comes to the treatment of serious burns, as well as respiratory tract infections.PACOBURNS has received funding of EUR 900,000 from France’s General Directorate for Armaments (Direction Générale de l’Armement - DGA)
|< Prev||Next >|